These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

505 related items for PubMed ID: 10430098

  • 1. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
    Shalinsky DR, Brekken J, Zou H, Bloom LA, McDermott CD, Zook S, Varki NM, Appelt K.
    Clin Cancer Res; 1999 Jul; 5(7):1905-17. PubMed ID: 10430098
    [Abstract] [Full Text] [Related]

  • 2. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Herbst RS, Hammond LA, Carbone DP, Tran HT, Holroyd KJ, Desai A, Williams JI, Bekele BN, Hait H, Allgood V, Solomon S, Schiller JH.
    Clin Cancer Res; 2003 Sep 15; 9(11):4108-15. PubMed ID: 14519633
    [Abstract] [Full Text] [Related]

  • 3. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials.
    Shalinsky DR, Brekken J, Zou H, McDermott CD, Forsyth P, Edwards D, Margosiak S, Bender S, Truitt G, Wood A, Varki NM, Appelt K.
    Ann N Y Acad Sci; 1999 Jun 30; 878():236-70. PubMed ID: 10415735
    [Abstract] [Full Text] [Related]

  • 4. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340.
    Price A, Shi Q, Morris D, Wilcox ME, Brasher PM, Rewcastle NB, Shalinsky D, Zou H, Appelt K, Johnston RN, Yong VW, Edwards D, Forsyth P.
    Clin Cancer Res; 1999 Apr 30; 5(4):845-54. PubMed ID: 10213221
    [Abstract] [Full Text] [Related]

  • 5. Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: effects on tumor neovascularization.
    Schiller JH, Bittner G.
    Clin Cancer Res; 1999 Dec 30; 5(12):4287-94. PubMed ID: 10632372
    [Abstract] [Full Text] [Related]

  • 6. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
    Marsland TA, Garfield DH, Khan MM, Look RM, Boehm KA, Asmar L.
    Lung Cancer; 2005 Jan 30; 47(1):111-20. PubMed ID: 15603861
    [Abstract] [Full Text] [Related]

  • 7. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).
    Lilenbaum RC, Herndon JE, List MA, Desch C, Watson DM, Miller AA, Graziano SL, Perry MC, Saville W, Chahinian P, Weeks JC, Holland JC, Green MR.
    J Clin Oncol; 2005 Jan 01; 23(1):190-6. PubMed ID: 15625373
    [Abstract] [Full Text] [Related]

  • 8. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
    Cohen RB, Langer CJ, Simon GR, Eisenberg PD, Hainsworth JD, Madajewicz S, Cosgriff TM, Pierce K, Xu H, Liau K, Healey D.
    Cancer Chemother Pharmacol; 2007 Jun 01; 60(1):81-9. PubMed ID: 17031646
    [Abstract] [Full Text] [Related]

  • 9. A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer.
    Yen WC, Corpuz MR, Prudente RY, Cooke TA, Bissonnette RP, Negro-Vilar A, Lamph WW.
    Clin Cancer Res; 2004 Dec 15; 10(24):8656-64. PubMed ID: 15623650
    [Abstract] [Full Text] [Related]

  • 10. The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells.
    Hermann TW, Yen WC, Tooker P, Fan B, Roegner K, Negro-Vilar A, Lamph WW, Bissonnette RP.
    Lung Cancer; 2005 Oct 15; 50(1):9-18. PubMed ID: 15993980
    [Abstract] [Full Text] [Related]

  • 11. The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression.
    Litz J, Sakuntala Warshamana-Greene G, Sulanke G, Lipson KE, Krystal GW.
    Lung Cancer; 2004 Dec 15; 46(3):283-91. PubMed ID: 15541812
    [Abstract] [Full Text] [Related]

  • 12. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance.
    Singh RP, Mallikarjuna GU, Sharma G, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R.
    Clin Cancer Res; 2004 Dec 15; 10(24):8641-7. PubMed ID: 15623648
    [Abstract] [Full Text] [Related]

  • 13. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
    Glorieux P, Ortmanns P, Marien S, Degives R, Degraeve D, Potvin M, Grauwels D, Schallier D.
    Anticancer Res; 2001 Dec 15; 21(2B):1487-94. PubMed ID: 11396237
    [Abstract] [Full Text] [Related]

  • 14. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
    Nemati F, Livartowski A, De Cremoux P, Bourgeois Y, Arvelo F, Pouillart P, Poupon MF.
    Clin Cancer Res; 2000 May 15; 6(5):2075-86. PubMed ID: 10815935
    [Abstract] [Full Text] [Related]

  • 15. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
    Zou Y, Fu H, Ghosh S, Farquhar D, Klostergaard J.
    Clin Cancer Res; 2004 Nov 01; 10(21):7382-91. PubMed ID: 15534115
    [Abstract] [Full Text] [Related]

  • 16. Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice.
    Ihnat MA, Nervi AM, Anthony SP, Kaltreider RC, Warren AJ, Pesce CA, Davis SA, Lariviere JP, Hamilton JW.
    Oncol Res; 1999 Nov 01; 11(7):303-10. PubMed ID: 10757444
    [Abstract] [Full Text] [Related]

  • 17. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
    Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, Lush R, Padilla B, Burton M, Williams C, Simon G, Antonia S, Sullivan DM, Bepler G.
    Clin Cancer Res; 2008 Mar 01; 14(5):1464-9. PubMed ID: 18316570
    [Abstract] [Full Text] [Related]

  • 18. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
    Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG.
    Clin Cancer Res; 2000 Dec 15; 6(12):4885-92. PubMed ID: 11156248
    [Abstract] [Full Text] [Related]

  • 20. Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Burris HA, Morrissey LH, Thomas M, Erland JB, Butts JA, Joseph G, Kalman L, Greco FA.
    Cancer J; 2000 Dec 15; 6(3):151-6. PubMed ID: 10882330
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.